Antibody-mediated prevention and treatment of HIV-1 infection (Q59339950)

Retroviridae infectious disease

19 September 2019

1 reference

19 October 2019

1 reference

27 November 2019

1 reference

13 December 2019

RNA virus infectious disease

1 reference

Creative Commons Attribution 4.0 International

1 July 2020

neutralizing antibody

1 reference

19 January 2021

1 reference

14 July 2021

Henning Gruell

1

0 references

Florian Klein

series ordinal

2

0 references

language of work or name

English

0 references

publication date

16 November 2018

10 references

25 June 2019

19 September 2019

19 October 2019

27 November 2019

13 December 2019

28 April 2020

1 July 2020

19 January 2021

14 July 2021

25 October 2022

10 references

25 June 2019

19 September 2019

19 October 2019

27 November 2019

13 December 2019

28 April 2020

1 July 2020

19 January 2021

14 July 2021

25 October 2022

15

0 references

issue

1

0 references

page(s)

73

0 references

copyright license

10 references

25 June 2019

19 September 2019

19 October 2019

27 November 2019

13 December 2019

28 April 2020

1 July 2020

19 January 2021

14 July 2021

Risk of human immunodeficiency virus type 1 transmission through breastfeeding

25 October 2022

cites work

1 reference

12 December 2020

An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection

1 reference

12 December 2020

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

1 reference

12 December 2020

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

12 December 2020

Lytic infection by British AIDS virus and development of rapid cell test for antiviral antibodies

1 reference

12 December 2020

Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

1 reference

12 December 2020

Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

1 reference

12 December 2020

hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120

1 reference

12 December 2020

Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody

1 reference

12 December 2020

Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma

1 reference

12 December 2020

Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The Passive Hyperimmune Therapy Study Group.

1 reference

12 December 2020

A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.

1 reference

12 December 2020

Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies

1 reference

12 December 2020

Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection

1 reference

12 December 2020

Immunological memory and protective immunity: understanding their relation

1 reference

12 December 2020

Clonal selection and learning in the antibody system

1 reference

12 December 2020

Sexual transmission of HIV.

1 reference

12 December 2020

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

12 December 2020

Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120

1 reference

12 December 2020

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.

1 reference

12 December 2020

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

12 December 2020

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

1 reference

12 December 2020

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

12 December 2020

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

12 December 2020

Passive immunity in prevention and treatment of infectious diseases

1 reference

12 December 2020

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

1 reference

12 December 2020

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

12 December 2020

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

1 reference

12 December 2020

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation

1 reference

12 December 2020

Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques

1 reference

12 December 2020

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

1 reference

12 December 2020

Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies

1 reference

12 December 2020

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

1 reference

12 December 2020

Monoclonal antibody hNM01 in HIV-infected patients: a phase I study

1 reference

12 December 2020

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

1 reference

12 December 2020

Bioinformatics-assisted anti-HIV therapy

1 reference

12 December 2020

Post-infection immunodeficiency virus control by neutralizing antibodies

1 reference

12 December 2020

Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection

1 reference

12 December 2020

FcRn: the neonatal Fc receptor comes of age.

1 reference

12 December 2020

Fc receptor but not complement binding is important in antibody protection against HIV.

1 reference

12 December 2020

A method for identification of HIV gp140 binding memory B cells in human blood

1 reference

12 December 2020

Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection.

1 reference

12 December 2020

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

1 reference

12 December 2020

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

1 reference

12 December 2020

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

1 reference

12 December 2020

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

1 reference

12 December 2020

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

1 reference

12 December 2020

Correlates of protection induced by vaccination

1 reference

12 December 2020

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

1 reference

12 December 2020

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

1 reference

12 December 2020

Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

1 reference

12 December 2020

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

1 reference

12 December 2020

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

1 reference

12 December 2020

Broad neutralization coverage of HIV by multiple highly potent antibodies

1 reference

12 December 2020

Antibody-based protection against HIV infection by vectored immunoprophylaxis

1 reference

12 December 2020

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques

1 reference

12 December 2020

Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model

1 reference

12 December 2020

Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus

1 reference

12 December 2020

A mouse model for HIV-1 entry

1 reference

12 December 2020

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

1 reference

12 December 2020

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

1 reference

12 December 2020

Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration

1 reference

12 December 2020

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques

1 reference

12 December 2020

Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies

1 reference

12 December 2020

Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1

1 reference

12 December 2020

Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques

1 reference

12 December 2020

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

1 reference

12 December 2020

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

1 reference

12 December 2020

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

1 reference

12 December 2020

Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission

1 reference

12 December 2020

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

1 reference

12 December 2020

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

1 reference

12 December 2020

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

1 reference

12 December 2020

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice

1 reference

12 December 2020

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo

1 reference

12 December 2020

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

1 reference

12 December 2020

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity

1 reference

12 December 2020

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants

1 reference

12 December 2020

MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide

1 reference

12 December 2020

Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1.

1 reference

12 December 2020

HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies

1 reference

12 December 2020

Tenofovir-based preexposure prophylaxis for HIV infection among African women

1 reference

12 December 2020

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

1 reference

12 December 2020

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

1 reference

12 December 2020

Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants.

1 reference

12 December 2020

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

1 reference

12 December 2020

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

1 reference

12 December 2020

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo

1 reference

12 December 2020

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

1 reference

12 December 2020

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

1 reference

12 December 2020

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

1 reference

12 December 2020

Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design

1 reference

12 December 2020

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

1 reference

12 December 2020

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

1 reference

12 December 2020

Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.

1 reference

12 December 2020

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

1 reference

12 December 2020

Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity

1 reference

12 December 2020

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

1 reference

12 December 2020

Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo

1 reference

12 December 2020

Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus

1 reference

12 December 2020

Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

1 reference

12 December 2020

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

1 reference

12 December 2020

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

1 reference

12 December 2020

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller

1 reference

12 December 2020

Early antibody therapy can induce long-lasting immunity to SHIV

1 reference

12 December 2020

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

1 reference

12 December 2020

Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys

1 reference

12 December 2020

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

1 reference

12 December 2020

Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys

1 reference

12 December 2020

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

1 reference

12 December 2020

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

1 reference

12 December 2020

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.

1 reference

12 December 2020

Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time.

1 reference

12 December 2020

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

1 reference

12 December 2020

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

1 reference

12 December 2020

Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells

1 reference

12 December 2020

Antibodies to watch in 2018.

1 reference

12 December 2020

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

1 reference

12 December 2020

Passive immunotherapy of viral infections: 'super-antibodies' enter the fray

1 reference

12 December 2020

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.

1 reference

12 December 2020

Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117

1 reference

12 December 2020

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

1 reference

12 December 2020

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

1 reference

12 December 2020

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

1 reference

12 December 2020

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

1 reference

12 December 2020